MENU
+Compare
HRMY
Stock ticker: NASDAQ
AS OF
Dec 18, 04:59 PM (EDT)
Price
$33.50
Change
-$0.13 (-0.39%)
Capitalization
1.92B

HRMY Harmony Biosciences Holdings Forecast, Technical & Fundamental Analysis

a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders

Industry Biotechnology
HRMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for HRMY with price predictions
Dec 17, 2024

HRMY sees its Stochastic Oscillator ascends from oversold territory

On December 17, 2024, the Stochastic Oscillator for HRMY moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 57 instances where the indicator left the oversold zone. In of the 57 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRMY advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .

HRMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 09, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on HRMY as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HRMY turned negative on December 09, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at .

HRMY moved below its 50-day moving average on November 29, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HRMY entered a downward trend on December 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.213) is normal, around the industry mean (14.664). P/E Ratio (15.938) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). HRMY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (2.861) is also within normal values, averaging (260.687).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
HRMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

HRMY is expected to report earnings to fall 13.33% to 68 cents per share on February 19

Harmony Biosciences Holdings HRMY Stock Earnings Reports
Q4'24
Est.
$0.68
Q3'24
Beat
by $0.12
Q2'24
Beat
by $1.04
Q1'24
Beat
by $0.25
Q4'23
Beat
by $0.01
The last earnings report on October 29 showed earnings per share of 79 cents, beating the estimate of 67 cents. With 178.71K shares outstanding, the current market capitalization sits at 1.92B.
A.I. Advisor
published General Information

General Information

a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
630 West Germantown Pike
Phone
+1 484 539-9800
Employees
246
Web
https://www.harmonybiosciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SFNNX10.97N/A
N/A
Schwab Fundamental Intl Equity Index Fd
IMAYX9.51-0.03
-0.31%
Delaware Ivy Multi-Asset Income Y
HNCCX15.62-0.08
-0.51%
Hartford International Growth C
JAWGX74.42-0.54
-0.72%
Janus Henderson VIT Global Rsrch Instl
PMAQX46.25-0.48
-1.03%
Principal MidCap R6

HRMY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with SNBIF. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then SNBIF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRMY
1D Price
Change %
HRMY100%
+1.72%
SNBIF - HRMY
52%
Loosely correlated
N/A
SAGE - HRMY
39%
Loosely correlated
-1.40%
ANAB - HRMY
39%
Loosely correlated
-3.96%
RVNC - HRMY
39%
Loosely correlated
-0.65%
GYRE - HRMY
38%
Loosely correlated
+11.31%
More